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Summary
 
A tetrameric recombinant major histocompatibility complex (MHC) class I–peptide complex
was used as a staining reagent in flow cytometric analyses to quantitate and define the pheno-
type of Gag-specific cytotoxic T lymphocytes (CTLs) in the peripheral blood of simian immu-
nodeficiency virus macaque (SIVmac)-infected rhesus monkeys. The heavy chain of the rhesus
 
monkey MHC class I molecule Mamu-A
 
*
 
01 and 
 
b
 
2
 
-microglobulin were refolded in the pres-
ence of an SIVmac Gag synthetic peptide (p11C, C–M) representing the optimal nine–amino
acid peptide of Mamu-A
 
*
 
01–restricted predominant CTL epitope to create a tetrameric
Mamu-A
 
*
 
01/p11C, C–M complex. Tetrameric Mamu-A
 
*
 
01/p11C, C–M complex bound to
T cells of SIVmac-infected, Mamu-A
 
*
 
01
 
1
 
, but not uninfected, Mamu-A
 
*
 
01
 
1
 
, or infected,
Mamu-A
 
*
 
01
 
2
 
 rhesus monkeys. Specific staining of peripheral blood mononuclear cells
(PBMC) from SIVmac-infected, Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys was only found in the cluster
of differentiation (CD)8
 
a
 
/
 
b
 
1
 
 T lymphocyte subset and the percentage of CD8
 
a
 
/
 
b
 
1
 
 T cells in
the peripheral blood of four SIVmac-infected, Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys staining with this
complex ranged from 0.7 to 10.3%. Importantly, functional SIVmac Gag p11C-specific CTL
activity was seen in sorted and expanded tetrameric Mamu-A
 
*
 
01/p11C, C–M complex–bind-
ing, but not nonbinding, CD8
 
a
 
/
 
b
 
1
 
 T cells. Furthermore, the percentage of CD8
 
a
 
/
 
b
 
1
 
 T cells
binding this tetrameric Mamu-A
 
*
 
01/p11C, C–M complex correlated well with p11C-specific
cytotoxic activity as measured in both bulk and limiting dilution effector frequency assays. Fi-
nally, phenotypic characterization of the cells binding this tetrameric complex indicated that
this lymphocyte population is heterogeneous. These studies indicate the power of this approach
for examining virus-specific CTLs in in vivo settings.
 
C
 
ytotoxic T lymphocytes (CTLs) play an important
role in containing virus spread in many viral infec-
tions. However, the activity of this cell population in vivo
has proven difficult to study because its evaluation has re-
lied on cumbersome, functional assays that require exten-
sive cell manipulation and lengthy in vitro periods of cell
cultivation. Altman et al. have recently reported that fluo-
rescence dye-coupled tetrameric MHC class I–peptide
complexes can specifically bind to subpopulations of
epitope-specific cluster of differentiation (CD)
 
1
 
8
 
1
 
 T cells,
raising the possibility that CTLs might be studied using
flow cytometric technology (1).
There is accumulating evidence for the importance of
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2
 
m, 
 
b
 
2
 
-microglobulin; 1-D IEF, one-dimen-
sional isoelectric focusing; APC, allophycocyanin; B-LCL, B lymphoblastoid
cell line; CD, cluster of differentiation; LDA, limiting dilution assay; mac,
macaque; p11C, 12–amino acid fragment of SIVmac 251 Gag (amino acids
179–190); p11C, C–M, 9–amino acid fragment of SIVmac 251 Gag
(amino acids 181–189); pCTL, precursor frequency of CTLs; SIV, simian
immunodeficiency virus.
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CTLs in controlling HIV-1 and simian immunodeficiency
virus replication in both primary and chronic infections (2–
6). We have been studying the role of this cellular immune
response in AIDS immunopathogenesis in the simian im-
munodeficiency virus (SIV)/macaque model of AIDS.
Much of this work has focused on the evaluation of SIV-
mac Gag recognition by CTL in rhesus monkeys express-
ing the HLA-A homologue molecule Mamu-A
 
*
 
01. In fact,
we have shown that CTL recognition of Gag in SIVmac-
infected or vaccinated Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys is re-
stricted to a single epitope, 12–amino acid fragment of
SIVmac 251 Gag (amino acid 179–190) (p11C), bound to
Mamu-A
 
*
 
01 (7). Through studying the monkeys’ response
to this dominant CTL epitope, we have been able to evalu-
ate efficiently a variety of novel vaccine strategies for elicit-
ing SIVmac-specific CTL responses and assess the role of
CTLs in containing the replication of SIVmac during pri-
mary and chronic infections (8–11).
In these studies, we have generated tetrameric Mamu-
A
 
*
 
01/p11C, C–M complex using the optimal nine–amino
acid fragment of SIVmac (amino acids 181–189) p11C, C-M
(12) and evaluated its binding specificity in PBMCs of SIV-
mac-infected, Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys. We demon-
strate that the enumeration of CD8
 
1
 
 T cells that bind this
complex in flow cytometric analyses correlates quantita-
tively with functional CTL activity and that this cell popu-
lation is phenotypically heterogeneous.
 
Materials and Methods
 
Tetrameric Mamu-A
 
*
 
01/p11C, C–M Complex Formation.
 
DNA
coding for the soluble domain of Mamu-A
 
*
 
01 with a GlySer
linker at the 3
 
9
 
 end was amplified by PCR with the 5
 
9
 
 primer GTC-
ACTGAATTCAGGAGGAATTTAAAATGGGCTCTCACTC-
CATGAAG and the 3
 
9
 
 primer CGCACTGGATCCCGGCTC-
CCATTTCAGGGTGTGGGGC, using a Mamu-A
 
*
 
01 plasmid
as the template (7). The PCR product was digested with EcoRI
and BamHI, and subcloned into the expression plasmid HLA-
A2/GlySer/BSP (BSP, BirA substrate peptide; reference 1), which
contains the BSP (13) at the 3
 
9
 
 end. The expressed protein was
refolded in vitro with human 
 
b
 
2
 
-microglobulin (
 
b
 
2
 
m) in the
presence of a specific peptide as described (14). The optimal
nine–amino acid fragment of SIVmac 251 Gag (amino acids 181–
189; p11C, C–M) CTPYDINQM (12) was used to induce refold-
ing of the MHC class I molecule. The Mamu-A
 
*
 
01/p11C, C–M
monomers were purified by gel filtration on a TSK SW
 
xl
 
 3,000
column (TosoHaas, Montgomeryville, PA; Fig. 1 
 
A
 
), and further
purified on a MonoQ column (Pharmacia, Piscataway, NJ) in 20
mM Tris (pH 8.0) with a gradient of NaCl from 0 to 0.5 M. The
monomer was then stored in PBS with protease inhibitors: 2 
 
m
 
M
PMSF (Sigma Chemical Co., St. Louis, MO), 1 mM dithiothreitol
(Sigma Chemical Co.), 1 
 
m
 
g/ml aprotinin (Sigma Chemical Co.),
0.7 mg/ml pepstatin A (Sigma Chemical Co.), 1 
 
m
 
g/ml leupep-
tine (Sigma Chemical Co.), and 1 
 
m
 
M EDTA (Sigma Chemical
Co.). The 43-kD peak from the gel filtration (Fig. 1 
 
A
 
) was im-
munoprecipitated with the anti–human MHC class I heavy
chain–specific mAb BB7.7 (American Type Culture Collection,
Rockville, MD) and run on a 15% reducing SDS/PAGE (Fig. 1
 
B
 
). Purified Mamu-A
 
*
 
01/p11C, C–M monomers were biotiny-
lated enzymatically with BirA enzyme (Avidity, Denver, CO),
following the manufacturer’s instructions. The efficiency of bioti-
nylation was between 75 and 95%. A TSK SW
 
xl
 
 3,000 column
was used to remove the free biotin from the monomers (Fig. 1
 
C
 
). To generate the Mamu-A
 
*
 
01/p11C, C–M tetramers, the bi-
otinylated monomers were mixed with FITC-labeled ExtrAvidin
(Sigma Chemical Co.) at a molar ratio of 4:1 and were purified
by gel filtration on a TSK SW
 
xl
 
 3,000 column (Fig. 1 
 
D
 
).
 
Animals.
 
Heparinized blood samples were obtained from
rhesus monkeys (
 
Macaca mulatta
 
) experimentally infected with un-
cloned SIVmac strain 251 and healthy uninfected rhesus mon-
keys. These animals were maintained in accordance with the
guidelines of the Committee on Animals for the Harvard Medical
School (Cambridge, MA) and the "Guide for the Care and Use of
Laboratory Animals" (Department of Health and Human Services
Publication, National Institutes of Health, No. 82–23, revised
1985).
 
Selection of Mamu-A
 
*
 
01
 
1
 
 Rhesus Monkeys.
 
The selection of
the 
 
Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys was carried out by using mon-
key B lymphoblastoid cell lines (B-LCLs) for one-dimensional
isoelectric focusing (1-D IEF; reference 15) and functional CTL
assays. In brief, the monkey B-LCLs were generated by trans-
forming PBMCs with 
 
Herpesvirus papio
 
 (16). Cells were 
 
35
 
S-
 
trans
 
-
labeled for 6 h at 37
 
8
 
C. Pelleted cells were lysed on ice in lysis
buffer, and lysates were precleared by incubating with protein
A–Sepharose CL-4B beads (Sigma Chemical Co.) alone and with
beads saturated with irrelevant antibodies. Immunoprecipitation
was performed by incubating the precleared lysates with protein
A–Sepharose CL-4B beads saturated with the mAb BB7.7. The
beads were washed and then treated with neuraminidase type
VIII (Sigma Chemical Co.). BB7.7 immunoprecipitates were an-
alyzed by 1-D IEF as described previously (15). The MHC class I
haplotypes of the B-LCLs selected as 
 
Mamu-A
 
*
 
01
 
1
 
 by 1-D IEF
were confirmed by conventional CTL assays. The selected B-LCL,
following pulsing with the peptide p11C, were assessed for sus-
ceptibility to lysis by in vitro cultured effector cells from SIVmac-
infected, Mamu-A
 
*
 
01
 
1
 
 rhesus monkeys. Those animals express-
ing a shared band detected by 1-D IEF and whose B-LCLs were
specifically lysed by effector cells from SIVmac-infected, Mamu-
A
 
*
 
01
 
1
 
 monkeys were noted to be Mamu-A
 
*
 
01
 
1
 
.
 
Cytotoxicity Assay.
 
Autologous B-LCLs were used as target
cells in functional CTL assays. B-LCLs were incubated with 50
 
m
 
g/ml p11C (EGCTPYDINQML) or the negative control pep-
tide p11B (ALSEGCTPYDIN) for 90 min during 
 
51
 
Cr labeling.
For effector cells, PBMCs from monkeys chronically infected
with SIVmac were cultured for 3 d at 10
 
6
 
 cells/ml with Con A (5
 
m
 
g/ml; Sigma Chemical Co.), washed, and then maintained for
another 7 to 11 d in medium supplemented with recombinant
human IL-2 (20 U/ml; provided by Hoffman–La Roche, Nutley,
NJ). Alternatively, PBMCs were mixed with p11C-pulsed irradiated
autologous PBMCs at a ratio of 1:1 and cultured for 3 d at a den-
sity of 10
 
6
 
 cells/ml. Cells were then maintained for another 7 to
11 d in medium supplemented with recombinant human IL-2 (20
U/ml) as described above. PBMCs cultured according to one of
these two protocols were then centrifuged over Ficoll-Hypaque
(Ficopaque; Pharmacia) and assessed as effector cells in a standard
 
51
 
Cr–release assay using U-bottomed microtiter plates containing
10
 
4
 
 target cells with effector cells at different E/T ratios. All wells
were established and assayed in duplicate. Plates were incubated
in a humidified incubator at 378C for 4 h. Specific release was
calculated as [(experimental release 2 spontaneous release)/(max-
imum release 2 spontaneous release)] 3 100. Spontaneous release
was ,20% of maximal release with detergent (1% Triton X-100;
Sigma Chemical Co.) in all assays.1375 Kuroda et al.
Limiting Dilution Assays. Freshly isolated PBMCs from mon-
keys chronically infected with SIVmac were cultured at 63–8,000
cells/well in 24 replicate wells of 96-well microtiter plates.
10,000 gamma-irradiated autologous PBMCs, which had been
previously pulsed with p11C for 1 h and washed two times, were
added to each well. These cultures were then maintained in 100 ml
of medium supplemented with the T cell growth factor Lym-
phocult T (Biotest AG, Dreieich, Germany) at 10 U/ml at 378C
for 14 d. Microcultures were fed at 5 and 10 d by the addition of
50  ml medium supplemented with 10 U/ml Lymphocult T.
Lymphocytes from each well were tested for cytotoxicity against
autologous B-LCLs labeled with peptide p11C or the control
peptide p11B. Supernatants were harvested and counted for ra-
dioactivity after a 4-h incubation at 378C. The fraction of nonre-
sponding wells was the percentage of wells in which 51Cr-release
did not exceed the mean plus three standard deviations of the
spontaneous release of the 24 control wells. The specific precur-
sor frequency of CTLs (pCTL) was estimated by the maximum
likelihood method by substraction of background values of con-
trol peptide–labeled B-LCLs (17).
Staining and Phenotypic Analysis of p11C-specific CD81 T
Cells. The mAbs used for this study were directly coupled to
PE, PE–Texas red (ECD), or allophycocyanin (APC). The fol-
lowing mAbs were used: anti-CD8a(OKT8)-PE (Dako Corp.,
Carpinteria, CA), anti-CD11a(25.3.1)-PE, anti-CD14(MY4)-PE,
anti-CD28(4B10)-PE, anti-CD45RA(2H4)-PE, anti-HLA-DR(I3)-
PE, and anti-CD8a/b(2ST8-5H7)-ECD (Coulter Corp., Miami,
FL). The mAb FN18 (gift from D.M. Neville, Jr., National Insti-
tutes of Health, Bethesda, MD), which recognizes rhesus monkey
CD3, was directly coupled to APC. The three reagents: FITC-
coupled tetrameric Mamu-A*01/p11C, C–M complex, anti-CD8a/
b-ECD, and anti–rhesus monkey CD3-APC were used either
with anti-CD8a-PE, anti-CD11a-PE, anti-CD28-PE, anti-
CD45RA-PE, or anti-HLA-DR-PE to perform four-color flow
cytometric analyses. 1 mg of FITC-coupled tetrameric Mamu-
A*01/p11C, C–M complex was used in conjunction with the di-
rectly labeled mAbs to stain either 100 ml of fresh whole blood or
2 3 105 lymphocytes isolated by density gradient centrifugation
over Ficoll-Hypaque after in vitro culture. Whole blood samples
were lysed using a COULTERÒ Immunoprep Reagent System
and a Q-Prep Workstation (Coulter Corp.). To reduce the back-
ground level of staining, the Q-Prep procedure was modified,
and lysed samples were washed with 1.0 ml PBS and centrifuged
for 3 min at 300 g. Similarly, the stained lymphocyte samples
were washed with 1.0 ml PBS and centrifuged for 3 min at 300 g.
The supernatants were decanted, cells were resuspended in 0.5 ml
PBS containing 1% paraformaldehyde, and then were maintained
for 24 h at 48C before flow cytometric analysis. Samples were an-
alyzed on a COULTERÒ EPICSÒ Elite ESP (Coulter Corp.)
equipped with argon and helium neon lasers, a gated amplifier,
and a 140-mm flow cell tip. The instrument was run at high
bandwidth and alignment was controlled on a daily basis using
DNA-CHECK EPICSÒ Alignment Fluorospheres (Coulter
Corp.) to maintain the same sensitivity levels during the entire
study. Linear performance in each channel was controlled using
the EPICSÒ Immuno-Brite Standards Kit (Coulter Corp.). Volt-
age and compensation levels were established using control sam-
ples of unstained cells for adjusting the negative/background lev-
els of fluorescence to the first log step and single-color stained
cells for adjusting spectral overlap. For analysis of whole blood
specimens, a single set of control samples was prepared from
whole blood of one animal on a daily basis. For analysis of in vitro
cultured cells, control samples were prepared from Ficoll-Hypaque
isolated lymphocytes of each culture. A total of 10,000 to 20,000
lymphocytes were analyzed in a manually set acquisition gate and
positive cutoffs for fluorescence were set to the first log step to in-
clude ,0.1% of nonstaining cells. Data analysis was performed
using the EPICSÒ Elite software (version 4.02; Coulter Corp.).
Data presentation was performed using WinMDI software ver-
sion 2.5 (Joseph Trotter, La Jolla, CA) and Microsoft PowerPoint
software version 4.0c (Microsoft Corp., Redmond, WA).
Sorting and Culture of CD8a/b1 T Cell Subsets from PBMCs of
SIVmac-infected Rhesus Monkeys. Sorting of potentially biohaz-
ardous specimens was performed on a COULTERÒ EPICSÒ
Elite ESP located in a dedicated biosafety level 3 area. The enrich-
ment level of the sorter settings were set electronically to achieve
enrichments of selected subsets of .99%. PBMCs were enriched
by Ficoll-Hypaque gradient centrifugation and stained with
FITC-coupled tetrameric Mamu-A*01/p11C, C–M complex,
anti-CD14-PE, anti-CD8a/b-ECD, and anti–rhesus monkey
CD3-APC for 20 min on ice. The cells were then washed twice
with PBS supplemented with 10% FCS and maintained on ice
until sorting. FITC-coupled tetrameric Mamu-A*01/p11C, C–M
complex positive and negative CD8a/b1 T cells, and CD141
monocytes were electronically gated and collected in sample
tubes cooled to 48C. The sorted cells were centrifuged at 300 g
for 10 min and the pellets were resuspended in RPMI 1640 con-
taining 10% FCS, 5 mg/ml Con A, and 20 U/ml IL-2. Equal
numbers of CD141 monocytes were cultured for 10 d either with
FITC-coupled tetrameric Mamu-A*01/p11C, C–M complex
positive or negative CD8a/b1 T cells. The p11C-specific stain-
ing of the CD8a/b1 T cells was investigated by flow cytometric
analysis and the cytotoxic activity was evaluated by performing a
standard 51Cr–release assay as described above.
Results
Tetrameric Mamu-A*01/p11C, C–M Complex Binds to the
CD8a/b1 Subset of T Cells from SIVmac-infected, Mamu-
A*011 Rhesus Monkeys. We initially sought to character-
ize the binding specificity of the tetrameric Mamu-A*01/
p11C, C–M complex. Since the TCRs of CD81 CTLs
recognize self-MHC class I–peptide complexes, we ex-
pected the tetrameric Mamu-A*01/p11C, C–M to bind
specifically to a subpopulation of CD81 T cells from SIV-
mac-infected, Mamu-A*011 rhesus monkeys, but not to
CD81 T cells from uninfected, Mamu-A*011 or SIVmac-
infected, Mamu-A*012 monkeys. PBMCs from three groups
of rhesus monkeys (three monkeys per group) were as-
sessed: SIVmac2 Mamu-A*011, SIVmac1 Mamu-A*012,
and SIVmac1 Mamu-A*011. Whole blood specimens from
these monkeys were analyzed by flow cytometry with
four-color staining using FITC-coupled tetrameric Mamu-
A*01/p11C, C–M complex to quantitate the percentage of
p11C-specific CD81 T cells. The mAbs used in this study
included anti-CD3, anti-CD8a, and anti-CD8a/b. Be-
cause of Fc receptor expression by B cells and monocytes,
we expected some nonspecific binding of the tetramer
complexes to these cell populations. However, we ex-
pected binding of tetramer complexes to T cells only in in-
fected animals expressing the appropriate MHC class I mol-
ecule. The CD8 molecule is expressed on T cells either as a
CD8a/a homodimer or a CD8a/b heterodimer (18–22).1376 Flow Cytometric Analysis of CTL in SIVmac-infected Rhesus Monkeys
Natural killer cells express the CD8 molecule only as an a/a
homodimer. Since T cells expressing the CD8a/a homodimer
do not necessarily interact in an MHC class I–restricted
fashion (23), we expected a higher binding of the tetramer
complex to CD8a/b1 T cells than to CD8a/a1 T cells.
We noticed some nonspecific binding of the Mamu-
A*01/p11C, C–M complex to a subset of B cells and
monocytes in all the animals studied (data not shown). Al-
though the T cells expressing CD8a/a but not CD8a/b
in the peripheral blood of the monkeys represented in oc-
casional animals up to 40% of the total CD81 T cells (data
not shown), almost all (.95%) Mamu-A*01/p11C, C–M
complex–binding T cells expressed the CD8a/b het-
erodimer (Fig. 2). Therefore, in evaluating Mamu-A*01/
p11C, C–M complex–binding cells by flow cytometry,
CD8a/b1 T cells were gated and expression of the CD3
molecule was determined as an internal control.
Tetrameric Mamu-A*01/p11C, C–M complex–binding
CD8a/b1 T cells were detected only in PBMCs of SIV-
mac-infected, Mamu-A*011 rhesus monkeys. The per-
centage of the positive cells ranged from 0.9 to 10.3% of
CD8a/b1 T cells (Fig. 3). Relatively small changes in the
percentage of tetrameric Mamu-A*01/p11C, C–M com-
plex–binding CD8a/b1 T cells were observed performing
repeated analyses on blood of individual monkeys over a
period of 8 mo (data not shown). No detectable staining
was seen of the CD8a/b1 T cells in PBMCs of the other
two groups of animals, indicating that the Mamu-A*01/
p11C, C–M complexes bound specifically to CD8a/b1 T
cells of SIVmac-infected, Mamu-A*011 rhesus monkeys.
Tetrameric Mamu-A*01/p11C, C–M Complex–binding
CD8a/b1 T Cells are p11C-specific CTLs. To character-
ize the function and specificity of the Mamu-A*01/p11C,
C–M complex–binding cells, CD8a/b1 T cells of a SIV-
mac-infected, Mamu-A*011 rhesus monkey were sorted
by flow cytometry into cell populations that stained posi-
tively or negatively with the Mamu-A*01/p11C, C–M tet-
ramer complex. Both cell populations were then expanded
after Con A stimulation in IL-2–containing medium for 10 d,
analyzed again by flow cytometry for Mamu-A*01/p11C,
C–M tetramer complex binding, and assayed for p11C-
specific CTL activity. Greater than 90% of the sorted tet-
rameric Mamu-A*01/p11C, C–M complex positive cells
still bound this complex after in vitro expansion. These
cells showed a high p11C-specific CTL activity, even at
very low effector to target ratios (.20% specific lysis at a
0.16:1 E/T ratio; Fig. 4). On the other hand, the CD8a/
b1 T cells that initially did not bind remained tetrameric
Mamu-A*01/p11C, C–M complex negative and had no
p11C-specific CTL activity (Fig. 4). Thus, all expanded
Figure 1. Tetrameric Mamu-A*01/p11C, C–M complex formation.
(A) Gel filtration profile of Mamu-A*01 monomer refolded with b2m and
p11C, C–M. (B) SDS/PAGE of the 43-kD peak shown in A immuno-
precipitated with anti–human heavy chain mAb BB7.7. The positions of
b2m and Mamu-A*01 are shown with arrows. (C) Gel filtration profile of
biotinylated Mamu-A*01/p11C, C–M monomer. (D) Gel filtration pro-
file of tetrameric Mamu-A*01/p11C, C–M avidin complex.
Figure 2. Tetrameric Mamu-A*01/p11C, C–M complex binds only to
the CD8a/b1 subset of T cells from PBMCs of four SIVmac-infected,
Mamu-A*011 rhesus monkeys. CD31 T cells were analyzed for binding
of CD8a/b and tetrameric Mamu-A*01/p11C, C–M complex.1377 Kuroda et al.
CD8a/b1 T cells with the potential to mediate p11C-spe-
cific lysis bound the tetrameric Mamu-A*01/p11C, C–M
complex.
Tetrameric Mamu-A*01/p11C, C–M Complex Staining of
T Cells Correlates with p11C-specific CTL Activity. Standard
methods for analyzing and quantifying antigen-specific
CTL activity involve functional assays performed on lym-
phocytes expanded in vitro after nonspecific or antigen-
specific stimulation. We sought to determine whether the
enumeration of tetrameric Mamu-A*01/p11C, C–M com-
plex–binding cells in PBMCs correlated quantitatively with
functional CTL activity measured using standard functional
assays. To this end we first compared tetrameric Mamu-
A*01/p11C, C–M complex staining of CD8a/b1 T cells
of an SIVmac-infected, Mamu-A*011 monkey before and
after in vitro expansion of PBMCs. A representative exper-
iment is shown in Fig. 5. CD8a/b1 T cells that bound this
complex increased from 10.3 to 22.4% after 12 d of culture
after nonspecific stimulation and showed p11C-specific
CTL activity of 73% lysis at an E/T ratio of 80:1 (Fig. 5,
top right). In vitro expansion after antigen-specific stimula-
tion with p11C-pulsed autologous PBMCs resulted in an
increase of cells binding this complex from 10.3 to 86.3%.
p11C-specific CTL activity of 74% lysis was detected using
these lymphocytes as effector cells at an E/T ratio of 10:1
(Fig. 5, bottom right). Similar experiments were performed
using PBMCs from three other SIVmac-infected, Mamu-
A*011, rhesus monkeys (Table 1).
A limiting dilution assay (LDA) is currently accepted as
the most precise method available for quantifying the pre-
cursor frequency of CTLs in PBMCs. In parallel with the
studies described above, we performed LDAs on PBMCs
of these four infected monkeys (Table 1). In fact, the rank
ordering of the tetrameric Mamu-A*01/p11C, C–M com-
plex staining of CD8a/b1 T cells of these monkeys was
in accordance with the quantification of p11C-specific
CTLs seen in both bulk and LDA functional assays. These
findings suggest that the cell staining with the tetrameric
complex should provide useful quantitative data in CTL
analyses.
Figure 3. Tetrameric Mamu-A*01/p11C, C–M complex binds specif-
ically to CD8a/b1 T cells from PBMCs of SIVmac-infected, Mamu-
A*011 rhesus monkeys. PBMCs of three groups of monkeys, three mon-
keys per group, were assessed: SIVmac2 Mamu-A*011 monkeys,
SIVmac1 Mamu-A*012 monkeys, and SIVmac1 Mamu-A*011 monkeys.
Flow cytometric analysis was performed on gated CD8a/b1CD31 T
cells stained with FITC-coupled tetrameric Mamu-A*01/p11C, C–M
complex.
Figure 4. Tetrameric Mamu-
A*01/p11C, C–M complex binds
p11C-specific CD8a/b1 CTLs.
Freshly isolated PBMCs from
SIVmac-infected, Mamu-A*011
rhesus monkey 403 were stained
with FITC-coupled tetrameric
Mamu-A*01/p11C, C–M com-
plex. CD8a/b1, Mamu-A*01/
p11C, C–M complex positive and
CD8a/b1, Mamu-A*01/p11C,
C–M complex negative cells were
sorted by flow cytometry and
expanded after Con A stimula-
tion for 10 d in IL-2–containing
medium. The cells were again
stained and analyzed by flow cy-
tometry, and the p11C-specific
CTL activity of each cell popula-
tion was assessed.1378 Flow Cytometric Analysis of CTL in SIVmac-infected Rhesus Monkeys
Tetrameric Mamu-A*01/p11C, C–M Complex–binding
CD8a/b1 T Cells in PBMCs of SIVmac-infected, Mamu-
A*011 Rhesus Monkeys Are Phenotypically Heterogeneous.
The phenotype of CD8a/b1 tetramer-binding cells of
SIVmac-infected, Mamu-A*011 rhesus monkeys was in-
vestigated by four-color flow cytometric analysis. CD8a/
b1 T cells were evaluated for binding of the tetrameric
Mamu-A*01/p11C, C–M complex and expression of CD11a,
CD28, CD45RA, and MHC class II DR. The tetrameric
complex–binding CD8a/b1 T cells in the peripheral
blood of all four animals showed a relatively high mean flu-
orescence in anti-CD11a staining (representative staining
for CD11a is shown in Fig. 6 A) and were predominantly
CD45RA2 (Table 2 and Fig. 6 B). (No anti-CD45RO
mAb is available that binds to rhesus monkey CD45RO.)
Interestingly, a heterogeneous expression of the CD28
molecule was observed investigating tetrameric complex–
binding CD8a/b1 T cells in this group of four rhesus
monkeys; these cells from two animals were predominantly
CD281 and from another animal predominantly CD282
(Table 2 and Fig. 6 C). This skewing in CD28 expression
on tetrameric complex–binding cells did not correlate with
Table 1. Tetrameric Mamu-A*01/p11C, C–M Complex Binding to T Cells Correlates with p11C-specific CTL Activity*
Monkey
Percent CD8a/b1 T cells stained
with Mamu-A*01/p11C, C–M‡
p11C-specific lysis§
(Percentage)
pCTL¶
(per 106 cells) Whole blood
Con A/IL-2
expanded
p11C-pulsed APC
expanded
Con A/IL-2
expanded (80.1)i
p11C-pulsed APC
expanded (10.1)i
403 10.3 22.4 86.3 73 74 279
138 2.1 2.1 25.8 31 69 46
297 0.9 1.5 37.2 28 61 ,3
348 0.7 0.5 5.1 22 15 ,3
*p11C, C–M represents the optimal 9–amino acid fragment of the SIV Gag 12–amino acid peptide p11C (12).
‡Staining with FITC-coupled tetrameric Mamu-A*01/p11C, C–M complex on gated CD8a/b T cells.
§Percent p11C-specific lysis was calculated as percent specific release by p11C-pulsed MHC class I–matched target cells minus the average of the
percent specific release by control peptide p11B-pulsed target cells.
iE/T ratio.
¶CTL precursor frequency for p11C per 106 PBMCs assessed by LDA.
Figure 5. Tetrameric Mamu-
A*01/p11C, C–M complex
staining of a lymphocyte popula-
tion correlates with its p11C-
specific CTL activity. Whole
blood specimen from a Mamu-
A*011, SIVmac-infected rhesus
monkey 403 were stained with
FITC-coupled tetrameric Mamu-
A*01/p11C, C–M complex.
Cells were expanded for 12 d in
IL-2–containing medium, either
after stimulation with Con A or
with p11C-pulsed irradiated au-
tologous PBMCs. The cells were
again stained and analyzed by
flow cytometry, and the p11C-
specific CTL activity of each cell
population was assessed.1379 Kuroda et al.
CD28 expression on the nonbinding CD8a/b1 T cells.
MHC class II DR expression was higher on tetrameric
complex binding cells from three of the four rhesus mon-
keys compared to their nonreactive CD8a/b1 T cells,
with  $50% of these cells expressing the MHC class II DR
molecule (Table 2 and Fig. 6 D).
Discussion
The use of a tetrameric MHC class I–peptide complex
was evaluated as a staining reagent for flow cytometric
analysis of a virus epitope–specific CTL response in SIV-
mac-infected rhesus monkeys. We found that this complex
bound specifically to a subset of CD8a/b1 T cells from in-
fected monkeys of the appropriate MHC class I haplotype.
Moreover, the percentage of CD8a/b1 T cells binding
this complex correlated well with epitope-specific func-
tional cytotoxic activity as measured in both bulk and lim-
iting dilution assays.
Significantly different estimates of HIV- and SIV-specific
CTL precursor cell numbers have been generated using
different techniques. Functional limiting dilution analysis, a
standard method for quantitating CTLs, has revealed a fre-
quency of HIV-1–specific pCTLs between 0.001 and 0.1%
of PBMCs in infected individuals (24–26). Higher levels of
pCTLs, ranging from 0.2 to 1% of T cells, have been esti-
mated when TCR complementarity determining region 3
(CDR3) sequences were used as molecular markers for in-
dividual CTL clones to estimate the frequency of these cells
in PBMCs (27). Staining with tetrameric MHC class I–pep-
tide complexes for evaluation of HIV-1 Gag- and Pol-spe-
cific CTLs has provided estimates of a similar order of mag-
nitude (1).
In this study we estimated pCTLs in the same lympho-
cyte population of SIVmac-infected rhesus monkeys using
both functional LDAs and tetramer staining technologies.
We also found a significant discrepancy in this rhesus mon-
key animal model when comparing the results obtained by
standard LDA and tetrameric Mamu-A*01/p11C, C–M
complex staining. The p11C-specific pCTLs as determined
by tetrameric Mamu-A*01/p11C, C–M complex staining
PBMCs of the four SIVmac-infected, Mamu-A*011 rhesus
monkeys ranged between 0.7 and 10.3% of CD8a/b1 T
cells, whereas the highest pCTL estimate arrived at by
LDAs was 0.02% of all PBMCs, which is equivalent to
0.1% of CD8a/b1 T cells. A number of factors may be
contributing to the substantial discrepancy between these
estimates. Different culture conditions used in LDAs can
generate very different precursor frequency estimates. Thus,
whether an anti-CD3 antibody is used to stimulate cells,
whether cells are cultured in the presence of a crude T cell
growth factor, or whether the antigen used in the assay is
an actively synthesized viral protein or a synthetic peptide
can have a substantial impact on the estimated pCTLs. It is
also possible that a cell population that can bind a single
peptide–MHC class I complex is functionally heteroge-
Figure 6. Phenotypic characterization of tetrameric Mamu-A*01/
p11C, C–M complex–binding CD8a/b1 T cells. A whole blood speci-
men from a Mamu-A*011, SIVmac-infected rhesus monkey 403 was
stained with FITC-coupled tetrameric Mamu-A*01/p11C, C–M com-
plex and four different PE-coupled mAbs (CD11a, CD28, CD45RA, and
HLA-DR). (A) Mean fluorescence (MF) values are indicated for the
CD11a staining. Upper left (UL) is the mean fluorescence of the CD11a
positive and Mamu-A*01/p11C, C–M negative CD8a/b1 T cell popu-
lation. Upper right (UR) is the mean fluorescence of the CD11a positive
and Mamu-A*01/p11C, C–M positive CD8a/b1 T cell population. (B–
D) Percentages of CD28, CD45RA, MHC class II DR, and tetrameric
Mamu-A*01/p11C, C–M complex positive or negative CD8a/b1 T
cells are indicated.
Table 2. Phenotypic Characterization of Tetrameric Mamu-A*01/
p11C, C–M Binding CD8a/b1 T Cells*
Monkey MamuA*01/p11C, C–M
Mm403 Mm138 Mm297 Mm348
21212121
CD28
1 53.5 2.9 13.6 1.4 87.6 0.7 80.2 0.3
2 36.5 7.1 84.4 0.6 11.5 0.2 19.1 0.4
CD45RA
1 37.2 1.7 63.1 0.2 77.5 0.2 51.2 0.1
2 52.8 8.3 34.9 1.8 21.6 0.7 48.1 0.6
MHC class II-DR
1 19.6 5.3 49.1 1.1 8.9 0.7 12.9 0.3
2 70.4 4.7 48.9 0.9 90.2 0.2 86.4 0.4
*Percent of Mamu-A*01/p11C, C–M complex positive (1) and nega-
tive (2) populations staining for expression of CD28, CD45RA, and
MHC class II DR (positive [1] and negative [2]) in PBMCs gated on
CD8a/b1 T cells.1380 Flow Cytometric Analysis of CTL in SIVmac-infected Rhesus Monkeys
neous, with only a fraction of the cells being capable of lys-
ing virus-infected target cells at any point in time.
In fact, the phenotypic characterization of the tetrameric
Mamu-A*01/p11C, C–M complex–binding cells suggests
that these cells are heterogeneous in individual monkeys.
Most of the Mamu-A*01/p11C, C–M–binding cells in
these studies expressed relatively high levels of CD11a and
did not express CD45RA, suggesting that they were mem-
ory rather than naive lymphocytes. This observation is in
agreement with Altman et al. who described a homoge-
neous phenotypic memory type profile (CD45RO1 and
CD62L2) for their MHC class I–peptide binding cells (1).
Previous studies have suggested that HIV-1–specific CTLs
are HLA-DR1 and CD282 (28–32). However, we found a
heterogeneous expression of CD28 and MHC class II DR
by the tetrameric complex–binding T cells. Heterogeneity
in expression of these molecules by the Mamu-A*01/
p11C, C–M–binding cells is consistent with the possibility
of heterogeneity in their function.
The percentage of circulating CD8a/b1 T cells that
bound the tetrameric Mamu-A*01/p11C, C–M complex
was remarkably constant over a period of months in three
of the four chronically SIVmac-infected rhesus monkeys
that we have studied. In the fourth animal, rhesus monkey
403, the percentage was much higher than in others, vary-
ing between 4.6 and 10.3%. However, there was consider-
able variability between the different animals in the per-
centage of CD8a/b1 peripheral blood T cells binding this
complex. A number of factors may lead to this variability.
A particularly high level of persistent antigenemia may
contribute to a persistent clonal expansion of CD8a/b1 vi-
rus-specific CTLs. In light of the recent demonstration that
vigorous CTL responses correlate with low virus load in
HIV-1–infected humans (33), this is an unlikely possibility.
It is possible that animals that maintain a high level of
CD41 T cell–mediated help may mount a persistently high
level of virus-specific CTLs. The number of infected ani-
mals that we have studied to date is too few to allow us to
assess this possibility.
The use of this approach for studying CTL responses in
vivo will, in the end, be limited only by the technique’s
sensitivity. As currently performed, this flow cytometry–
based technique can detect CTLs only if they are repre-
sented in .0.1 to 0.5% of the CD8a/b1 T cell population.
A number of technical changes in this approach would
probably significantly enhance its sensitivity. Changes in
the dye and/or different laser configurations might increase
the ability to discriminate between tetramer binding and
nonbinding CD8a/b1 T cell populations. Such changes
might make it possible to examine CTL responses to less
dominant epitopes than the Mamu-A*01–restricted Gag
peptide evaluated in this study.
The application of this novel technology in the SIVmac-
infected rhesus monkey provides an important new ap-
proach for studying the role of CTLs in the immunopatho-
genesis of AIDS. It also provides a simple and quantitative
approach for evaluating potential new vaccine strategies for
preventing AIDS virus infections.
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